Regression of metastatic non-small-cell lung cancer in a chemonaive patient treated with gefitinib ('Iressa', ZD1839)

被引：0
|
作者：
Petruzelka, L [1 ]
Zemanova, M [1 ]
机构：
[1] Charles Univ Prague, Univ Hosp, Prague, Czech Republic
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [41] Clinically meaningful response to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    BRITISH JOURNAL OF CANCER, 2003, 89 : S28 - S28
  • [42] New hope for patients with non-small-cell lung cancer: gefitinib ('Iressa', ZD 1839) and other innovative therapies
    Goss, G
    EJC SUPPLEMENTS, 2003, 1 (08): : 1 - 1
  • [43] Refractory non-small-cell lung cancer: clinical experience with gefitinib ('Iressa', ZD1839) in 28 patients who entered the 'Iressa' Expanded Access Programme at the Sydney Cancer Centre
    Boyer, M
    BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S26
  • [44] Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
    A M Kirby
    R P A'Hern
    C D'Ambrosio
    M Tanay
    K N Syrigos
    S J Rogers
    C Box
    S A Eccles
    C M Nutting
    K J Harrington
    British Journal of Cancer, 2006, 94 : 631 - 636
  • [45] Outcomes of patients with advanced non-small cell tung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study
    Jänne, PA
    Gurubhagavatula, S
    Yeap, BY
    Lucca, J
    Ostler, P
    Skarin, AT
    Fidias, P
    Lynch, TJ
    Johnson, BE
    LUNG CANCER, 2004, 44 (02) : 221 - 230
  • [46] Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program
    Razis, E
    Skarlos, D
    Briasoulis, E
    Dimopoulos, M
    Fountzilas, G
    Lambropoulos, S
    Rigatos, S
    Kopterides, P
    Efstathiou, H
    Tzamakou, E
    Bakoyannis, C
    Pectasides, D
    Makatsoris, T
    Varthalitis, G
    Papadopoulos, S
    Kosmidis, R
    ANTI-CANCER DRUGS, 2005, 16 (02) : 191 - 198
  • [47] Clinically meaningful response case to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer
    Gelibter, A
    Ceribelli, A
    Milella, M
    Mottolese, M
    Vocaturo, A
    Cognetti, F
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (03) : 481 - 485
  • [48] Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ('Iressa', ZD1839)
    Tanno, S
    Ohsaki, Y
    Nakanishi, K
    Toyoshima, E
    Kikuchi, K
    ONCOLOGY REPORTS, 2004, 12 (05) : 1053 - 1057
  • [49] Getitinib (ZD1839, Iressa®) in non-small-cell lung cancer:: a review of clinical trials from a daily practice perspective
    Barlési, F
    Tchouhadjian, C
    Doddoli, C
    Villani, P
    Greillier, L
    Kleisbauer, JP
    Thomas, P
    Astoul, P
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (03) : 385 - 393
  • [50] Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer
    Nakamura, H
    Takamori, S
    Fujii, T
    Ono, M
    Yamana, H
    Kuwano, M
    Shirouzu, K
    CANCER LETTERS, 2005, 230 (01) : 33 - 46
12345